TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Isoniazid (Primary) ; Rifapentine (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms iAdhere
- 18 May 2016 Results of post-hoc analysis of two phase III studies (PREVENT TB and iAdhere) presented at the 112th International Conference of the American Thoracic Society
- 01 Dec 2012 Additional lead trial centre added as reported by European Clinical Trials Database record.
- 01 Dec 2012 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-002094-58).